Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2019-04-15 Regulatory Filings
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Familial Adenomatous Polyposis (news with additional features)
Regulatory Filings Classification · 100% confidence The document is a 'News Details' release dated April 15, 2019, originating from MorphoSys AG, disseminated via DGAP (a service of EQS Group AG). It announces a specific corporate event: the expansion of clinical development for Guselkumab (Tremfya(R)) into Familial Adenomatous Polyposis (FAP) by its licensee Janssen, and the receipt of a milestone payment. This type of announcement, detailing operational updates, clinical trial progress, and associated financial events (like milestone payments) that are not full financial statements (10-K, IR) or formal voting results, typically falls under general corporate news or regulatory announcements. Since it is a specific, time-sensitive update about business operations and drug development, it is best classified as a general Regulatory Filing (RNS) as it is a broad category for corporate news disseminated via regulatory channels (DGAP) that doesn't fit the more specific categories like ER, CAP, or DIV. It is not a full report, an earnings release, or a management discussion.
2019-04-15 English
MorphoSys Nominates New Candidate for Supervisory Board (news with additional features)
AGM Information Classification · 98% confidence The document is a news release announcing that MorphoSys has published its agenda for the upcoming Annual General Meeting (AGM) and is nominating a new candidate for the Supervisory Board. The key phrases are 'Nominates New Candidate for Supervisory Board' and 'published its agenda for the Company’s ordinary Annual General Meeting (AGM)'. This content directly relates to the preparation and agenda setting for the AGM, which falls under the 'AGM Information' category. Although it mentions the publication of the agenda, the core content is the nomination and the context of the upcoming meeting, making AGM-R more specific than RPA or RNS.
2019-04-10 English
MorphoSys AG: Bekanntmachung der Einberufung zur Hauptversammlung am 22.05.2019 in Planegg mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 99% confidence The document is titled 'Einladung zur ordentlichen Hauptversammlung 2019 der MorphoSys AG' (Invitation to the Annual General Meeting 2019 of MorphoSys AG) and explicitly lists the 'Tagesordnung' (Agenda). The agenda items include the presentation of the annual financial statements, discharge of management/supervisory board members, election of auditors, and several proposals related to changes in the supervisory board structure and remuneration. This content is characteristic of the formal notice and agenda distributed to shareholders in preparation for an Annual General Meeting (AGM). Although it mentions the annual financial statements (related to 10-K/AR), the primary purpose and format of this document is the official convocation for the AGM. Therefore, the most appropriate classification is AGM-R.
2019-04-10 German
MorphoSys to Present at Upcoming Investor Conferences
Report Publication Announcement Classification · 99% confidence The document is a news release dated April 9, 2019, announcing that MorphoSys AG will be presenting at upcoming investor conferences (Kempen Life Sciences Conference and Class of 2018 Biotech IPOs Investor Day). It details the dates, venues, and presenters for these events. This type of announcement, which informs investors about future opportunities to hear company updates, aligns best with the Investor Presentation (IP) category, as the company is actively engaging with investors, often using presentation materials. Although it is an announcement, the core subject is the presentation itself, making IP a stronger fit than a general RPA or RNS, as it specifically relates to investor engagement materials.
2019-04-09 English
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details a transaction involving a member of the managing body (Dr. Simon Moroney) concerning the acceptance of stock options. This directly corresponds to the definition of Director's Dealing (DIRS). The document length is short, but the content is the primary disclosure itself, not an announcement of a report.
2019-04-05 English
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section detailing 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It lists the name of a board member (Jens Holstein), the reason for notification (Member of the managing body), and details of a transaction involving the acceptance of stock options. This content directly matches the definition for Director's Dealing.
2019-04-05 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.